Newport Biotechnology Consultants, founded in 2005, originally was aimed at providing writing expertise in the life sciences industry, with a specialization in molecular immunology. I drew upon my academic and industrial background to cover new developments and technologies in antibody therapies and related areas of biotechnology. These reviews were published in a number of trade journals, especially articles in Genetic Engineering and Biotechnology News (see articles). More recently I have expanded my writing into other fields, including emergency management, drug discovery, bioprocessing, environmental and sustainable technologies, micro- and nanotechnology and many other areas. I also am involved in regulatory issues. I am Chair of the Meridian Bioscience Institutional Biosafety Committee, and I am a member of the Cincinnati Children’s Medical Center Institutional Biosafety Committee (see consulting services). Both IBCs review research protocols dealing with the use of recombinant DNA. Finally, I have consulted for a number of companies on laboratory design, business plan evaluation and regulatory questions.